ReviewNuclear medicine and molecular imaging2017
Current Status and Future Direction of Nanomedicine: Focus on Advanced Biological and Medical Applications.
Review in Nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 27 citations in OpenAlex.
- Nanotechnology Applications in Breast Cancer Immunotherapy.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- Nanoparticle-Mediated Drug Delivery Systems for Precision Targeting in Oncology.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Employing Gamma-Ray-Modified Carbon Quantum Dots to Combat a Wide Range of Bacteria.Antibiotics (Basel, Switzerland) · 2023Article
- An Engineered Specificity of Anti-Neoplastic Agent Loaded Magnetic Nanoparticles for the Treatment of Breast Cancer.Polymers · 2021Article
- Biocompatibility of nanomaterials and their immunological properties.Biomedical materials (Bristol, England) · 2021Review
- Strategies for the functionalisation of gold nanorods to reduce toxicity and aid clinical translation.Nanotheranostics · 2021Review
- Innovative approaches for cancer treatment: current perspectives and new challenges.Ecancermedicalscience · 2019Article
- Hyperthermia-Triggered Gemcitabine Release from Polymer-Coated Magnetite Nanoparticles.Polymers · 2018Article
- Fundamentals and commercial aspects of nanobiosensors in point-of-care clinical diagnostics.3 Biotech · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanotechnology is the engineering and manipulation of materials and devices with sizes in the nanometer range. Colloidal gold, iron oxide nanoparticles and quantum dot semiconductor nanocrystals are examples of nanoparticles, with sizes generally ranging from 1 to 20 nm. These nanotechnologies have been researched tremendously in the last decade and this has led to a new area of "nanomedicine" which is the application of nanotechnology to human health-care for diagnosis, monitoring, treatment, prediction and prevention of diseases. Recently progress has been made in overcoming some of the difficulties in the human use of nanomedicines. In the mid-1990s, Doxil was approved by the FDA, and now various nanoconstructs are on the market and in clinical trials. However, there are many obstacles in the human application of nanomaterials. For translation to clinical use, a detailed understanding is needed of the chemical and physical properties of particles and their pharmacokinetic behavior in the body, including their biodistribution, toxicity, and biocompatibility. In this review, we provide a broad introduction to nanomedicines and discuss the preclinical and clinical trials in which they have been evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.